Top stocks to buy: Stock recommendations for September 15, 2026 week - check list

These opinions do not represent the views of The Times of India.) Emcure Pharmaceuticals continues to strengthen its domestic and international pharmaceutical franchise through broad-based growth across Europe, Canada and ROW markets, supported by improved execution, niche products and a strong commercial network. Management expects low-to-mid teen revenue growth with 70-100bp EBITDA margin expansion in FY27, supported by continued international growth, new product launches and stronger domestic execution. Mortgage is becoming the key growth engine alongside the core vehicle-finance franchise, while gold loans, consumer finance and MSME add higher-yielding, more diversified earnings streams.Margins stay resilient even as funding costs tick up. At ~4.1x FY27E P/BV, CIFC trades above vehicle-financing peers, but we see this as justified by superior growth, improving returns and broader diversification.

Source: Times of India September 15, 2026 03:03 UTC